Acquisition of Shares
24/11/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221124:nRSX4107Ha&default-theme=true
RNS Number : 4107H Clarify Pharma PLC 24 November 2022
The information contained within this announcement is deemed by the Company to
constitute inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014, as retained as part of the law of England and Wales. Upon
the publication of this announcement via the Regulatory Information Service,
this inside information is now considered to be in the public domain.
Press Release
24 November 2022
Clarify Pharma PLC
("Clarify Pharma" or "The Company")
Acquisition of Shares in Atai Life Sciences and Compass Pathways
Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and
life sciences companies seeking to prove the safety and efficacy of
psychedelic-based substances, is pleased to announce it has acquired shares to
the value of £250,000 in each of Atai Life Sciences Inc (NASDAQ: ATAI) and
Compass Pathways PLC (NASDAQ: CMPS) as part of its investment strategy.
Atai Life Sciences Inc is a leading biotech company specialised in
psychedelic-based drugs and has prominent backing from venture capitalists,
including entrepreneur and venture capitalist Peter Thiel. Atai's pipeline
features nine programs, four of which are in the clinical testing stage. The
company's lead drug candidate, RL-007, is being evaluated in a Phase 2
clinical study as a potential treatment for schizophrenia. Furthermore, Atai's
Perception Neuroscience unit partnered with Otsuka, the Japanese drugmaker, to
develop R-ketamine in treating depression. This represented the first major
collaboration between a psychedelic-focused biotech and a big pharmaceutical
company. Atai has also acquired and made several strategic investments in
companies in the sector.
Compass Pathways PLC was founded in 2015 to support the research and
development of psilocybin therapy which combines the pharmacological effects
of psilocybin, a psychoactive substance, with psychological support for the
treatment of mental health challenges. Compass Pathways conducted the largest
clinical trial in the history of psilocybin-assisted therapy with a Phase 2
study evaluating a synthesised formulation of psilocybin, COMP360, in
treatment-resistant depression. This research is now into late-stage testing.
Compass Pathways has also initiated a Phase 2 study of the therapy in treating
post-traumatic stress disorder at The Institute of Psychiatry, Psychology
& Neuroscience at King's College London.
Jonathan Bixby, Executive Chairman of Clarify Pharma, said: "I am delighted to
announce Clarify Pharma's purchase of shares in two trailblazing companies
which are conducting pioneering research into psychedelic-assisted therapeutic
treatment. Clarify Pharma continues to pursue new and exciting opportunities
in the sector and is focused on delivering value for shareholders as investors
continue to gain confidence in the regulatory environment for alternative
treatments."
For further information please contact:
Clarify Pharma
Jon Bixby via Tancredi +44 207 887 7633
Executive Chairman
First Sentinel
Corporate Adviser +44 7876 888 011
Brian Stockbridge
Tennyson Securities
Corporate Broker +44 207 186 9030
Peter Krens
Tancredi Intelligent Communication
Media Relations
Catrina Daly +44 7727 153 868
Salamander Davoudi +44 7957 549 906
clarifypharma@tancredigroup.com
About Clarify Pharma PLC:
Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment
vehicle focusing on investing in biotech and life sciences companies seeking
to prove the safety and efficacy of psychedelic-based substances. The Company
looks to identify investment opportunities in the life sciences sector within
the UK, Canada and other growing markets, with the objective of generating
long-term capital growth and building investments in an R&D pipeline of
companies which are discovering, developing, or deploying safe and
evidence-based psychedelic inspired medicines and experiential therapies that
alleviate mental health problems and enhance wellbeing.
The Company's Directors have an established track record, experience and
networks in the psychedelic, cannabinoid and media industries, to drive value
creation.
https://www.clarifypharma.com/ (https://www.clarifypharma.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXEAXFDAAFAFFA